NCT00460499

Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 250 (actual)
• Sponsor: American Heart Association · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study seeks to determine whether varying the dose of insulin and glucose in diabetic patients during coronary bypass surgery will improve outcomes in these patients.

Detailed description

Our previous study has shown that maintaining serum glucose between 120-180mg/dl in the perioperative period during CABG surgery in diabetic patients improves outcomes. The purpose of this trial is: (1) to determine whether outcomes can be improved by altering the content of glucose or insulin in these solutions (2)to determine the effect of these solutions and glycemic control on the inflammatory response of arterial and venous conduits used during surgery, (3) to determine whether the beneficial effects of improved glycemic control can be correlated with changes in the inflammatory response.

Conditions

• Glycemic Control

Interventions

Type	Name	Description
DRUG	A IV Insulin drip	These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
DRUG	B Low Dose GIK	These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
DRUG	C High Dose GIK	This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl

Timeline

• Start date: 2004-07-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2007-04-16
• Last updated: 2015-06-23

Locations

1 site across 1 country: United States